FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008952789> ?p ?o ?g. }

• W3008952789 endingPage "751" @default.
• W3008952789 startingPage "751" @default.
• W3008952789 abstract "751 Background: Biomarkers to select mRCC patients most likely to benefit to immune-checkpoint inhibitors are still needed. The ongoing retrospective multicentre Meet-URO 15 (I-BIO-REC) study evaluates the prognostic role of peripheral blood cells in mRCC patients treated with nivolumab. Methods:The primary endpoint of the study was median overall survival (mOS) according to baseline neutrophil to lymphocyte ratio (NLR), but here preliminary analyses on baseline LMR and SII (secondary endpoints) are reported. LMR was defined as the ratio of lymphocyte to monocyte (cutoff = 3) and SII as platelet x neutrophil/lymphocyte (cutoff = 1375). Results: From May 2016 to January 2019 189 patients started nivolumab as 2nd (62%), 3rd (25%) and > 3rd (13%) line. Median age was 69 years, 67% were male and 87% had clear cell histology. Baseline IMDC group was favorable in 26%, intermediate in 63% and poor in 11%. Lymph-nodes, visceral and bone metastases were present in 55%, 92% and 37%. mOS and progression-free survival (PFS) were 30.5 months and 9.5 months. Overall response rate (ORR) and disease control rate (DCR) were 28% and 57%. LMR was available in 150 patients: LMR ≥ 3 (44%) correlated with statistically significant longer OS [NR vs 26.8 months, HR 0.50 (0.29-0.88); p = 0.016] but not PFS (10.3 vs 9.9 months, HR 0.87 (0.58-1.31); p = 0.5) with similar ORR (34% vs 33%) and DCR (60% vs 63%) compared to LMR < 3. SII was available in 162 patients. SII < 1375 (82%) correlated with statistically significant longer PFS [11.5 vs 3.4 months; HR 2.16 (1.36-3.43), p = 0.001] and OS [NR vs 9.5 months; HR 3.87 (2.21-6.78), p < 0.001] with higher ORR (35% vs 20%) and DCR (65% vs 40%) compared to SII ≥ 1375. Univariate and multivariate analyses adjusted for IMDC group, line of therapy and metastatic sites, confirmed the statistically significant correlation between SII with PFS and OS, but not for LMR. Conclusions: Preliminary analyses of our study showed a prognostic role of baseline SII, while it is uncertain for LMR in mRCC patients treated with nivolumab." @default.
• W3008952789 created "2020-03-06" @default.
• W3008952789 creator A5012508480 @default.
• W3008952789 creator A5013505561 @default.
• W3008952789 creator A5013913173 @default.
• W3008952789 creator A5019981707 @default.
• W3008952789 creator A5028388712 @default.
• W3008952789 creator A5040427285 @default.
• W3008952789 creator A5043134225 @default.
• W3008952789 creator A5049661977 @default.
• W3008952789 creator A5050343624 @default.
• W3008952789 creator A5057926104 @default.
• W3008952789 creator A5060954139 @default.
• W3008952789 creator A5061243125 @default.
• W3008952789 creator A5063795761 @default.
• W3008952789 creator A5071060598 @default.
• W3008952789 creator A5077284495 @default.
• W3008952789 creator A5077883336 @default.
• W3008952789 creator A5080840934 @default.
• W3008952789 creator A5081353003 @default.
• W3008952789 creator A5081355165 @default.
• W3008952789 creator A5091765229 @default.
• W3008952789 date "2020-02-20" @default.
• W3008952789 modified "2023-10-14" @default.
• W3008952789 title "Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study." @default.
• W3008952789 doi "https://doi.org/10.1200/jco.2020.38.6_suppl.751" @default.
• W3008952789 hasPublicationYear "2020" @default.
• W3008952789 type Work @default.
• W3008952789 sameAs 3008952789 @default.
• W3008952789 citedByCount "4" @default.
• W3008952789 countsByYear W30089527892020 @default.
• W3008952789 countsByYear W30089527892021 @default.
• W3008952789 countsByYear W30089527892022 @default.
• W3008952789 crossrefType "journal-article" @default.
• W3008952789 hasAuthorship W3008952789A5012508480 @default.
• W3008952789 hasAuthorship W3008952789A5013505561 @default.
• W3008952789 hasAuthorship W3008952789A5013913173 @default.
• W3008952789 hasAuthorship W3008952789A5019981707 @default.
• W3008952789 hasAuthorship W3008952789A5028388712 @default.
• W3008952789 hasAuthorship W3008952789A5040427285 @default.
• W3008952789 hasAuthorship W3008952789A5043134225 @default.
• W3008952789 hasAuthorship W3008952789A5049661977 @default.
• W3008952789 hasAuthorship W3008952789A5050343624 @default.
• W3008952789 hasAuthorship W3008952789A5057926104 @default.
• W3008952789 hasAuthorship W3008952789A5060954139 @default.
• W3008952789 hasAuthorship W3008952789A5061243125 @default.
• W3008952789 hasAuthorship W3008952789A5063795761 @default.
• W3008952789 hasAuthorship W3008952789A5071060598 @default.
• W3008952789 hasAuthorship W3008952789A5077284495 @default.
• W3008952789 hasAuthorship W3008952789A5077883336 @default.
• W3008952789 hasAuthorship W3008952789A5080840934 @default.
• W3008952789 hasAuthorship W3008952789A5081353003 @default.
• W3008952789 hasAuthorship W3008952789A5081355165 @default.
• W3008952789 hasAuthorship W3008952789A5091765229 @default.
• W3008952789 hasConcept C121608353 @default.
• W3008952789 hasConcept C126322002 @default.
• W3008952789 hasConcept C126894567 @default.
• W3008952789 hasConcept C141071460 @default.
• W3008952789 hasConcept C168563851 @default.
• W3008952789 hasConcept C203092338 @default.
• W3008952789 hasConcept C2777472916 @default.
• W3008952789 hasConcept C2777701055 @default.
• W3008952789 hasConcept C2777761686 @default.
• W3008952789 hasConcept C2780030458 @default.
• W3008952789 hasConcept C71924100 @default.
• W3008952789 hasConcept C90924648 @default.
• W3008952789 hasConceptScore W3008952789C121608353 @default.
• W3008952789 hasConceptScore W3008952789C126322002 @default.
• W3008952789 hasConceptScore W3008952789C126894567 @default.
• W3008952789 hasConceptScore W3008952789C141071460 @default.
• W3008952789 hasConceptScore W3008952789C168563851 @default.
• W3008952789 hasConceptScore W3008952789C203092338 @default.
• W3008952789 hasConceptScore W3008952789C2777472916 @default.
• W3008952789 hasConceptScore W3008952789C2777701055 @default.
• W3008952789 hasConceptScore W3008952789C2777761686 @default.
• W3008952789 hasConceptScore W3008952789C2780030458 @default.
• W3008952789 hasConceptScore W3008952789C71924100 @default.
• W3008952789 hasConceptScore W3008952789C90924648 @default.
• W3008952789 hasIssue "6_suppl" @default.
• W3008952789 hasLocation W30089527891 @default.
• W3008952789 hasOpenAccess W3008952789 @default.
• W3008952789 hasPrimaryLocation W30089527891 @default.
• W3008952789 hasRelatedWork W2792937256 @default.
• W3008952789 hasRelatedWork W2909056931 @default.
• W3008952789 hasRelatedWork W2994993125 @default.
• W3008952789 hasRelatedWork W3006775906 @default.
• W3008952789 hasRelatedWork W4212804027 @default.
• W3008952789 hasRelatedWork W4281645962 @default.
• W3008952789 hasRelatedWork W4282980498 @default.
• W3008952789 hasRelatedWork W4310753920 @default.
• W3008952789 hasRelatedWork W4316038761 @default.
• W3008952789 hasRelatedWork W4376133623 @default.
• W3008952789 hasVolume "38" @default.
• W3008952789 isParatext "false" @default.
• W3008952789 isRetracted "false" @default.
• W3008952789 magId "3008952789" @default.
• W3008952789 workType "article" @default.